Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Carlino, Matteo S.
Au-Yeung, George
Spillane, Andrew J. http://orcid.org/0000-0002-9520-0181
Shannon, Kerwin F. http://orcid.org/0000-0001-8538-3132
Gyorki, David E.
Hsiao, Edward http://orcid.org/0000-0003-4882-0297
Kapoor, Rony
Thompson, Jake R.
Batula, Iris
Howle, Julie
Ch’ng, Sydney http://orcid.org/0000-0002-4011-1253
Gonzalez, Maria
Saw, Robyn P. M. http://orcid.org/0000-0002-3354-806X
Pennington, Thomas E.
Lo, Serigne N. http://orcid.org/0000-0001-5092-5544
Scolyer, Richard A. http://orcid.org/0000-0002-8991-0013
Menzies, Alexander M.
Funding for this research was provided by:
GVL is supported by an NMHRC Investigator Grant and The University of Sydney Medical Foundation
IB is supported by The Bill and Patricia Ritchie foundation.
RPMS is supported by Melanoma Institute Australia.
RAS is supported by an NHMRC Investigator Grant
AMM is supported by an NMHRC Investigator Grant, Nicholas and Helen Moore and Melanoma Institute Australia
Article History
Received: 4 March 2024
Accepted: 17 May 2024
First Online: 21 June 2024
Competing interests
: G.V.L. is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., IOBiotech Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR, Pierre Fabre and Regeneron. A.M.M. is a consultant advisor for Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis, Pierre Fabre, QBiotics and Roche. M.S.C. has served on advisory boards or as a consultant for Amgen, Bristol Myers Squibb, Eisai, Ideaya, Merck Sharpe & Dohme, Nektar, Novartis, Oncosec, Pierre Fabre, Qbiotics, Regeneron, Roche, Merck and Sanofi, and received honoraria from Bristol Myers Squibb, Merck Sharpe & Dohme and Novartis. D.E.G. has served on the advisory board for Amgen and received honoraria from Bristol Myers Squibb and Merck Sharpe & Dohme. R.P.M.S. has received honoraria for advisory board participation from Merck Sharpe & Dohme, Novartis and Qbiotics and speaking honoraria from Bristol Myers Squibb and Novartis. R.A.S. has received fees for professional services from Amgen, Bristol Myers Squibb, Evaxion, GlaxoSmithKline, Merck Sharp & Dohme, MetaOptima Technology, Myriad Genetics, NeraCare, Novartis, Provectus, Qbiotics and Roche. All other authors declare no competing interests.